Metastatic Renal Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

University Hospital Bonn Study Enhances Therapy Response Prediction in Metastatic Renal Cell Carcinoma Patients

University Hospital Bonn Study Enhances Therapy Response Prediction in Metastatic Renal Cell Carcinoma Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Nordrhein westfalenJonas saalInstitute for experimental oncologyDepartment of urologyPediatric urology of the university hospital bonnPediatric urologyUniversity hospital bonnExperimental oncologyMedical clinicGlasgow prognosis scorePredict responseMetastatic renal cell

ASCO 2023: When to Play the Systemic Therapy Card

ASCO 2023: When to Play the Systemic Therapy Card
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkKaren runcieKaplan meierKarie runcieDivision of hematology oncologyDepartment of internal medicineColumbia university irving medical centerAmerican society of clinical oncologySociety of urologic oncologyDatabase consortiumInternational metastaticUniversity of torontoClinical oncologyAssistant professorInternal medicine

Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

Optimizing outcomesPatients withTranslating evidenceClinical practiceMetastatic renal cellRenal cell carcinomaKidney cancerMetastatic rccMetastatic kidney cancerAdvanced rccAdvanced kidney cancerIntermediate riskPoor riskIpi nivoNivo ipiTrio therapy

Discoveries & Impact (February 2023)

Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine.

United statesSouth koreaSri lankaKimg smolderenMario strazzaboscoYale hepatologistsCarlos mena hurtadoMultimorbidity comorbidityAriel jaffeJohns hopkinsMultimorb comorbDepartment of internal medicineYale diabetes centerInterest group of the american thoracic societySociety of vascular surgerySectional north american

Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless

France generalUnited statesUnited kingdomDennis riedlBradley mcgregorMauricio burottoAntoine thiery vuilleminLaurence albigesPhilippe barthIpsen euronextPaul nathanTonik choueiriAnand sharmaBradford hill clinical research centerTakeda pharmaceutical companyEuropean union